Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Haemozoin is a dark-brown biocrystal synthesized by hematophagous parasites, most notably Plasmodium species, to detoxify free heme released during the digestion of host hemoglobin [1, 2]. Since free heme is highly toxic to the parasite due to its ability to generate reactive oxygen species and damage membranes, its conversion into the insoluble, chemically inert haemozoin crystal is essential for parasite survival [1, 9]. This biocrystallization process occurs within the parasite's acidic food vacuole and is a primary target for several classes of antimalarial drugs, particularly the quinolines [4, 7]. Drugs like chloroquine bind to the growing crystal faces or to free heme, preventing further crystallization and causing the accumulation of toxic heme that ultimately kills the parasite [2, 7]. Beyond its role in parasite survival, haemozoin acts as a potent immunomodulator in the host, contributing to the inflammatory response and clinical symptoms of malaria, such as anemia and fever [6, 8].
Inhibition of haemozoin biocrystallization
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Haemozoin (HZ).